Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 531 in Patients With Advanced Malignancy Receiving Chemotherapy
NCT00147225Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2005
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of romiplostim in Thrombocytopenia (6 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events. Started Aug 2005; status: completed.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00147225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147225.